Novo Nordisk Lines Up Twelve Liver Abstracts for AASLD as Lilly's Retatrutide Data Sharpens the Competitive Lens
Published on 10/28/2026 at 19:10 | Editorial boerse-global.de
Novo Nordisk will put twelve scientific abstracts on the board at next month's Liver Meeting of the American Association for the Study of Liver Diseases, the company said, spanning semaglutide and the investigational drug efruxifermin. The conference runs from 5 to 9 November, with Novo's own presentations scheduled for 6 to 8 November.
For shareholders, the announcement is first and foremost a data calendar entry. Fresh results could sharpen the read on both compounds, but a clinical win cannot be inferred from the disclosure itself. Novo is explicit that efruxifermin remains an investigational agent, so none of the twelve abstracts should be confused with a regulatory decision.
Real-world MASH comparison takes centre stage
Beyond the headline count, the programme carries a specific hook: comparative data drawn from clinical practice on semaglutide against resmetirom in MASH. That pits the two treatments in a real-world setting rather than a controlled trial, which makes the substance of the findings — and the conclusions they support — the thing to watch.
The distinction matters. A conference abstract is a date for assessing research, not evidence of commercial progress already banked.
CagriSema shows why subgroup readouts need careful framing
How easily a single analysis can be over-read is illustrated by the CagriSema data published on 20 October. A post-hoc analysis of the Phase 3 REDEFINE 1 trial showed average weight loss of 25.0% among women at week 68, contingent on treatment adherence. Novo labelled the analyses exploratory, and the caveat is central: a subgroup result is not the same as the trial-wide outcome.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Reuters reported on 20 October that the analysis covered 2,309 women. Across the full study population, the reported weight reduction was 22.7% — below the company's own 25% target. In the placebo arm, weight loss came in at 3%.
A direct Lilly comparison raises the bar
The valuation question for Novo investors is no longer simply how strong its own trial signals are, but how well they hold up against rival data. Reuters reported that Eli Lilly's experimental retatrutide beat Ozempic 2 mg on blood-sugar control in a head-to-head study of adults with type 2 diabetes, and delivered more than double the weight loss. The findings come from Lilly.
Retatrutide is experimental, so the result does not yet amount to a market shift. As a competitive signal, though, a direct comparison carries weight — and it sets a different yardstick than looking at Novo's own positive results in isolation. Lilly's reported advantage spanned both glycaemic control and weight loss, meaning the signal is not confined to a single endpoint.
Keeping the two datasets apart
Novo's post-hoc REDEFINE 1 analysis covers a female subgroup and was generated after the fact. It should be read as a specific efficacy signal, not as a direct rebuttal to Lilly's Ozempic comparison — a different investigational drug, a different comparator and, explicitly, adults with type 2 diabetes.
The constructive case rests on investors judging Novo on more than the latest Ozempic comparison. Strong CagriSema data do not refute Lilly's result, but they can stop a single rival comparison from becoming the whole valuation story. That scenario requires no claim of superiority over retatrutide; it simply asks that the positive finding be acknowledged alongside its limited reach. The risk runs the other way: if Lilly's head-to-head data dominate perceptions while Novo's subgroup result carries less conviction, the pressure on Novo's competitive standing would build — without yet describing a settled commercial outcome. Equally, it would be a stretch to read the Ozempic comparison as proven inferiority for CagriSema.
A regulatory win sits on a separate track
Novo reported a different stage of development on Friday for Awiqli. According to the company, the FDA approved the once-weekly basal insulin to improve blood-sugar control in children aged ten and older with type 2 diabetes. That approval stands clearly apart from the liver abstracts: Awiqli has a concrete regulatory decision behind it, while the congress contributions centre on scientific findings.
The next real test of today's announcement is therefore the content of the November presentations — not the number of abstracts, but what they actually show.
The calendar's next marker
The nearer fixed date is 4 November 2026, when Novo Nordisk is due to publish third-quarter and first-nine-months 2026 results before the market opens. That gives investors the next opportunity to weigh clinical competitive signals against the underlying business. The core judgement remains how much forward confidence Novo's own development data can justify in the face of a direct rival comparison.
Ad
Novo Nordisk Stock: New Analysis - 28 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
